Maple Securities USA’s BioMarin Pharmaceuticals BMRN Stock Holding History

Maple Securities USA’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,237	Closed	-$443K	–	60
2015 Q2	$443K	Buy	+3,237	New	+$401K	0.04%	141

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Maple Securities USA's BMRN Position: Q3 2015 in Review

Maple Securities USA sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2015, closing a stake of 3,237 shares — an estimated $443K sold.

Maple Securities USA first reported a position in BMRN in Q2 2015 and held it in 1 quarter. The position peaked at $443K in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

Maple Securities USA reported no remaining BioMarin Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Maple Securities USA sold 3,237 BioMarin Pharmaceuticals shares in Q3 2015, an estimated $443K.
Maple Securities USA first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 1 quarter.
Maple Securities USA's BioMarin Pharmaceuticals position peaked at $443K in Q2 2015.
393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Maple Securities USA's 13F filing for Q3 2015, filed 3 Nov 2015.